Argenx SE(ARGX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARGX Argenx SE

休市中 08-07 16:00:00 EDT

865.04

-10.26

-1.17%

盘后865.04

+0.000.00%

19:40 EDT

最高894.03	最低862.60	成交量25.00万
今开890.47	昨收875.30	日振幅3.59%
总市值540.98亿	流通市值540.21亿	总股本6,254万
成交额2.18亿	换手率0.40%	流通股本6,245万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARGX","market":"US","secType":"STK","nameCN":"Argenx SE","latestPrice":865.04,"timestamp":1786132800000,"preClose":875.3,"halted":0,"volume":250018,"hourTrading":{"tag":"盘后","latestPrice":865.04,"preClose":865.04,"latestTime":"19:40 EDT","volume":459,"amount":397042.24,"timestamp":1786146046763,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011721695418713575,"floatShares":62449100,"shares":62537923,"eps":26.213955,"marketStatus":"休市中","change":-10.26,"latestTime":"08-07 16:00:00 EDT","open":890.47,"high":894.03,"low":862.6,"amount":217989544.1172,"amplitude":0.035908,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":26.213955,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786348800000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":1495080000000,"exchange":"NASDAQ","adjPreClose":875.3,"preHourTrading":{"tag":"盘前","latestPrice":891.8362,"preClose":875.3,"latestTime":"09:29 EDT","volume":143,"amount":127415.7313,"timestamp":1786109386081,"change":16.5362,"changeRate":0.018892,"amplitude":0.008208},"postHourTrading":{"tag":"盘后","latestPrice":865.04,"preClose":865.04,"latestTime":"19:40 EDT","volume":459,"amount":397042.24,"timestamp":1786146046763,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8911681251550565,"impliedVol":0.4316,"impliedVolPercentile":0.9243},"requestUrl":"/m/hq/s/ARGX","defaultTab":"news","newsList":[{"id":"2657314546","title":"Argenx SE（ARGX）正式发起要约收购 拟全现金吞并Forte（FBRX）","url":"https://stock-news.laohu8.com/highlight/detail?id=2657314546","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657314546?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:37","pubTimestamp":1786019826,"startTime":"0","endTime":"0","summary":"Argenx拟以每股77.00美元的现金价格收购Forte所有已发行及流通在外的普通股，要约收购自2026年8月6日正式开启，将于美东时间2026年8月26日到期。不过，该交易还需要获得代表Forte已发行股份超50%的有效预先要约与接纳，也须符合美国HSR法案的等待期届满或提前终止。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/Mjk1NzA2YjQxMDg1MTQ0MjI1MzE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Mjk1NzA2YjQxMDg1MTQ0MjI1MzE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303516","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVNT","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","BK4585","BK4588","LU0109394709.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4505","LU0823416689.USD","IE00B4R5TH58.HKD","BK4139","ARGX","LU0320765992.SGD","TBXU","IE0002141913.USD","LU1983260115.SGD","IE00BJT1NW94.SGD","FMED","LU2324357040.USD","FBRX","IBB","IE0034235188.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119188140","title":"异动解读｜Argenx SE盘中下跌3.01%，豪掷22亿美元现金收购Forte Biosciences引发市场消化","url":"https://stock-news.laohu8.com/highlight/detail?id=1119188140","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119188140?lang=zh_cn&edition=full","pubTime":"2026-07-28 03:57","pubTimestamp":1785182225,"startTime":"0","endTime":"0","summary":"消息面上，公司宣布将以每股77美元、总计约22亿美元的现金收购Forte Biosciences，溢价约40%。此次收购旨在将Forte的核心项目FB102纳入管线，拓展其免疫学药物组合，该项目针对乳糜泻的二期临床数据预计于下半年公布。尽管Wedbush将Argenx目标价从1000美元上调至1050美元，维持跑赢大盘评级，但作为收购方，大额现金支出及整合不确定性使股价短期承压，被收购方Forte Biosciences则大涨39.7%，呈现典型的并购交易双方股价分化格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654097843","title":"Argenx(ARGX.US)豪掷22亿美元、溢价40%收购Forte Biosciences(FBRX.US) 加码布局免疫学药物组合","url":"https://stock-news.laohu8.com/highlight/detail?id=2654097843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654097843?lang=zh_cn&edition=full","pubTime":"2026-07-27 14:52","pubTimestamp":1785135121,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ARGX","BK4585","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4588","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","IBB","LU2324357040.USD","LU1983260115.SGD","IE0002141913.USD","IE0034235188.USD","FBRX","BK4139","IE0009355771.USD","LU0889565916.HKD","LU0320765992.SGD","BK4505","IE00B2B36J28.USD","TBXU","FMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145887507","title":"Argenx豪掷22亿美元、溢价40%收购Forte Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=1145887507","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145887507?lang=zh_cn&edition=full","pubTime":"2026-07-27 13:08","pubTimestamp":1785128915,"startTime":"0","endTime":"0","summary":"7月27日，ForteBiosciences美股夜盘飙升逾22%，Argenx将以每股77美元的价格对其进行现金收购。全球免疫学创新公司 argenx和Forte Biosciences, Inc.今天宣布，两家公司已达成最终协议，根据该协议，argenx 将以每股 77 美元的现金收购 Forte Biosciences，总股权价值约为 22 亿美元。Forte Biosciences 的主导项目 FB102 的加入，进一步拓展了 argenx 的差异化免疫学药物产品组合。此次收购体现了 argenx 严谨的研发策略，致力于为患者发现并推进突破性科学，以期重新定义数十年来缺乏实质性创新疗法的疾病的治疗标准。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Argenx豪掷22亿美元、溢价40%收购Forte Biosciences","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBRX","ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154039515","title":"异动解读｜Argenx SE盘中上涨6.88%，Q2业绩大幅超预期推动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1154039515","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154039515?lang=zh_cn&edition=full","pubTime":"2026-07-24 00:12","pubTimestamp":1784823177,"startTime":"0","endTime":"0","summary":"7月23日，Argenx SE盘中上涨6.88%，报910.34美元/股，成交额2.53亿美元。消息面上，公司于当日盘前发布第二季度财报，业绩大幅超出市场预期。季度净利润攀升至4.72亿美元，较去年同期的2.45亿美元近乎翻倍。基本面来看，核心产品Vyvgart在获得FDA全血清型适应症扩展批准后处方转化持续放量，CIDP患者份额预期从18%升至23%，叠加公司截至6月底拥有52亿美元现金储备，为后续研发及商业化扩张提供充裕资金支持。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119182867","title":"异动解读 | 财报业绩强劲，Argenx SE盘中大涨5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119182867","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119182867?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:10","pubTimestamp":1784815835,"startTime":"0","endTime":"0","summary":"Argenx SE今日盘中大涨5.33%，引发市场广泛关注。消息面上，公司于盘前发布了2026年第二季度及上半年财报，业绩表现极为亮眼。数据显示，公司第二季度产品净销售额达到15.16亿美元，同比大幅增长60%，环比增长17%；季度净利润攀升至4.72亿美元，较去年同期的2.45亿美元近乎翻倍。2026年上半年，公司产品净销售额累计达28.13亿美元，净利润达8.38亿美元，均较去年同期显著提升。强劲的业绩增长与积极的管线预期共同提振了市场信心，推动股价盘中走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166453652","title":"异动解读 | Q2业绩强劲增长，Argenx SE盘前大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166453652","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166453652?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:10","pubTimestamp":1784808637,"startTime":"0","endTime":"0","summary":"Argenx SE今日盘前大涨5.17%，引发市场广泛关注。消息面上，公司于盘前发布了2026年第二季度及上半年财报，业绩表现极为亮眼。数据显示，公司第二季度产品净销售额达到15.16亿美元，同比大幅增长60%，环比增长17%；季度净利润攀升至4.72亿美元，较去年同期的2.45亿美元近乎翻倍。强劲的业绩增长与积极的管线预期共同提振了市场信心，推动股价盘前走强。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653749341","title":"argenx(ARGX)二季度产品净销售额达15.16亿美元 同比增长60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653749341","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653749341?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:18","pubTimestamp":1784801894,"startTime":"0","endTime":"0","summary":"金吾财讯 | 全球自身免疫疾病龙头生物科技公司 argenx 发布了2026年第二季度及上半年财报。其中，2026年第二季度，公司实现产品净销售额 15.16亿美元，同比大幅增长 60%，环比增长 17%。资金储备方面，截至2026年6月30日，argenx 拥有的现金、现金等价物及流动金融资产达 52亿美元，显著高于2025年底的44亿美元，为后续临床研发及商业化扩张提供了雄厚的资金屏障。截至2026年底，argenx 预计将有10款药物分子处于临床研发阶段。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ODM0ODU4NWZiOGY2NDQ4NTA4OTM0NDg5MTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ODM0ODU4NWZiOGY2NDQ4NTA4OTM0NDg5MTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE0034235188.USD","BK4505","ARGX","IE00BJT1NW94.SGD","IE0009355771.USD","BK4139","IBB","BK4588","IE00B4R5TH58.HKD","BK4585","LU0889565916.HKD","IE0002141913.USD","LU0320765992.SGD","LU2324357040.USD","IE00BJJMRZ35.SGD","TBXU","IE00BFTCPJ56.SGD","LU1983260115.SGD","IE00B2B36J28.USD","FMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172337789","title":"异动解读｜Argenx SE盘中上涨3.25%，财报发布前夕市场看多情绪升温","url":"https://stock-news.laohu8.com/highlight/detail?id=1172337789","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172337789?lang=zh_cn&edition=full","pubTime":"2026-07-22 03:41","pubTimestamp":1784662874,"startTime":"0","endTime":"0","summary":"7月22日，Argenx SE盘中上涨3.25%，报873.67美元/股，成交额1.86亿美元。消息面上，公司将于7月23日盘前发布Q2财报，市场一致预期本季度营收14.43亿美元，同比增长53.14%；调整后每股收益预计6.15美元，同比增长81.68%。此前多家机构给予买入评级，BNP Paribas给出1219美元目标价。核心产品Vyvgart在获得FDA全血清型适应症扩展批准后，处方转化持续放量，叠加CIDP患者份额预期从18%升至23%，基本面支撑财报前的乐观预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138281652","title":"财报前瞻｜Argenx SE本季度营收预计增53.14%，机构观点看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1138281652","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138281652?lang=zh_cn&edition=full","pubTime":"2026-07-16 08:41","pubTimestamp":1784162472,"startTime":"0","endTime":"0","summary":"Argenx SE将于2026年07月23日美股盘前发布最新季度财报，市场关注核心产品放量与扩适应证后的处方转化节奏。一致预期显示，本季度Argenx SE营收预计为14.43亿美元，同比增长53.14%；调整后每股收益预计6.15美元，同比增长81.68%；同时，息税前利润预计4.35亿美元，同比增长131.46%，当前一致预期未见对本季度毛利率和净利润或净利率的明确披露，故不展示相关预测信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Argenx SE本季度营收预计增53.14%，机构观点看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122187562","title":"异动解读｜Argenx SE盘中下跌3.66%，报876.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122187562","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122187562?lang=zh_cn&edition=full","pubTime":"2026-07-11 00:13","pubTimestamp":1783700024,"startTime":"0","endTime":"0","summary":"7月11日，Argenx SE盘中下跌3.66%，报876.24美元/股，成交额1.78亿美元。Argenx SE所在的生物科技行业中，整体表现疲弱，个股中，艾伯维公司跌1.35%，Ionis Pharmaceuticals跌8.74%，Moderna跌10.51%，吉利德科学跌3.24%，阿尔尼拉姆制药公司跌4.30%。Argenx SE是一家处于商业阶段的全球性生物制药公司，核心产品Vyvgart用于治疗严重自身免疫性疾病，公司下次财报将于7月23日盘前发布。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166643955","title":"异动解读｜Argenx SE盘中上涨3.02%，报935.745美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166643955","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166643955?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:06","pubTimestamp":1783001192,"startTime":"0","endTime":"0","summary":"7月2日，Argenx SE盘中上涨3.02%，报935.745美元/股，成交额4630.24万美元。Argenx SE所在的生物科技行业中，整体表现偏强，个股中，Moderna涨10.69%，Abivax S.A.涨8.97%，艾伯维公司涨1.43%，福泰制药涨3.21%，Propanc Biopharma涨42.36%。Argenx SE是一家处于商业阶段的全球性生物制药公司，核心产品Vyvgart用于治疗严重自身免疫性疾病，目前已获批用于全血清型广泛性重症肌无力及慢性炎症性脱髓鞘多神经病变等适应症。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127918059","title":"异动解读｜Argenx SE盘中下跌3.05%，报899.435美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127918059","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127918059?lang=zh_cn&edition=full","pubTime":"2026-07-02 00:51","pubTimestamp":1782924700,"startTime":"0","endTime":"0","summary":"7月1日，Argenx SE盘中下跌3.05%，报899.435美元/股，成交额2.0亿美元。Argenx SE所在的生物科技行业中，整体表现分化，个股中，艾伯维公司跌0.6%，Abivax S.A.涨0.74%，安进跌0.63%，Can-Fite Biopharma涨42.63%，吉利德科学跌0.16%。Argenx SE是一家处于商业阶段的全球性生物制药公司，核心产品Vyvgart用于治疗严重自身免疫性疾病，目前已获批用于全血清型广泛性重症肌无力及慢性炎症性脱髓鞘多神经病变等适应症。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123056084","title":"异动解读｜Argenx SE盘中上涨4.21%，法国巴黎银行给予跑赢大盘评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1123056084","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123056084?lang=zh_cn&edition=full","pubTime":"2026-06-26 00:15","pubTimestamp":1782404105,"startTime":"0","endTime":"0","summary":"6月25日，Argenx SE盘中上涨4.21%，报887.71美元/股，成交额2.36亿美元。消息面上，法国巴黎银行近日首次覆盖Argenx，给予\"跑赢大盘\"评级，目标价1,219美元，较当前股价隐含约37%的上行空间，明显高于市场共识目标价1,064.53美元，对市场情绪形成持续提振。此外，公司核心产品Vyvgart已于今年5月获FDA批准扩展至全血清型重症肌无力患者，叠加一季度EPS 5.52美元超预期，基本面支撑推动股价延续涨势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159712045","title":"异动解读｜Argenx SE盘前上涨3.55%，法国巴黎银行给予跑赢大盘评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1159712045","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159712045?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:07","pubTimestamp":1782288430,"startTime":"0","endTime":"0","summary":"6月24日，Argenx SE盘前上涨3.55%，报868.83美元/股，成交额2.03万美元。消息面上，法国巴黎银行近日将Argenx评级为\"跑赢大盘\"，并给出1,219美元的目标价，较当前股价隐含约40%的上行空间。据FactSet数据，该股分析师平均评级为\"买入\"，平均目标价为1,064.53美元。法国巴黎银行的目标价明显高于市场共识，对市场情绪形成积极提振，推动股价延续近日涨势。Argenx SE是一家处于商业阶段的全球性生物制药公司，专注开发用于治疗严重自身免疫性疾病的差异化疗法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178462515","title":"异动解读｜Argenx SE夜盘上涨5.46%，法国巴黎银行给予跑赢大盘评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1178462515","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178462515?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:02","pubTimestamp":1782284520,"startTime":"0","endTime":"0","summary":"6月24日，Argenx SE夜盘上涨5.46%，报900.0美元/股，成交额5.13万美元。消息面上，法国巴黎银行近日将Argenx评级为\"跑赢大盘\"，并给出1,219美元的目标价，较当前股价隐含较大上行空间。据FactSet数据，该股分析师平均评级为\"买入\"，平均目标价为1,064.53美元。法国巴黎银行的目标价明显高于市场共识，对市场情绪形成积极提振，推动股价延续近日涨势。Argenx SE是一家处于商业阶段的全球性生物制药公司，专注开发用于治疗严重自身免疫性疾病的差异化疗法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195743704","title":"异动解读｜Argenx SE盘中上涨3.08%，法国巴黎银行给予跑赢大盘评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1195743704","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195743704?lang=zh_cn&edition=full","pubTime":"2026-06-24 00:39","pubTimestamp":1782232759,"startTime":"0","endTime":"0","summary":"6月23日，Argenx SE盘中上涨3.08%，报931.58美元/股，成交额1.34亿美元。消息面上，法国巴黎银行近日将Argenx评级为\"跑赢大盘\"，并给出1,219美元的目标价，较当前股价隐含约31%的上行空间。据FactSet数据，该股分析师平均评级为\"买入\"，平均目标价为1,064.53美元。法国巴黎银行的目标价明显高于市场共识，对市场情绪形成积极提振。Argenx SE是一家处于商业阶段的全球性生物制药公司，专注开发用于治疗严重自身免疫性疾病的差异化疗法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197954784","title":"异动解读｜Argenx SE盘中上涨3.71%，法国巴黎银行给予跑赢大盘评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1197954784","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197954784?lang=zh_cn&edition=full","pubTime":"2026-06-23 00:13","pubTimestamp":1782144810,"startTime":"0","endTime":"0","summary":"6月23日，Argenx SE盘中上涨3.71%，报910.27美元/股，成交额1.9亿美元。消息面上，法国巴黎银行近日将argenx评级为\"跑赢大盘\"，并给出1,219美元的目标价，较当前股价隐含约34%的上行空间。据FactSet数据，该股分析师平均评级为\"买入\"，平均目标价为1,064.53美元。法国巴黎银行的目标价明显高于市场共识，对市场情绪形成积极提振。Argenx SE是一家处于商业阶段的全球性生物制药公司，专注开发用于治疗严重自身免疫性疾病的差异化疗法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107841283","title":"异动解读｜Argenx SE盘中上涨6.11%，报894.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107841283","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107841283?lang=zh_cn&edition=full","pubTime":"2026-06-06 00:15","pubTimestamp":1780676152,"startTime":"0","endTime":"0","summary":"6月6日，Argenx SE盘中上涨6.11%，报894.36美元/股，成交额3.9亿美元。Argenx SE所在的生物科技行业中，个股中，BioCardia涨34.34%，安进涨2.54%，艾伯维公司涨1.92%，福泰制药涨1.46%，吉利德科学涨1.11%。Argenx SE是一家处于商业阶段的全球性生物制药公司，专注于开发用于治疗严重自身免疫性疾病的差异化疗法，公司于2008年在荷兰成立，2014年转为上市有限责任公司。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170531813","title":"财报前瞻｜Argenx SE本季度营收预计增65.79%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1170531813","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170531813?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:10","pubTimestamp":1777515039,"startTime":"0","endTime":"0","summary":"Argenx SE将于2026年05月07日盘前发布季度财报，市场聚焦Vyvgart放量与利润弹性。市场一致预期本季度Argenx SE营收为13.19亿美元，同比增长65.79%；调整后每股收益为5.38美元，同比增长134.87%；EBIT为4.08亿美元，同比增长230.92%，一致预期暂未提供毛利率与净利润或净利率的具体预测，公司上季度披露材料中未见针对本季度的明确营收指引。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Argenx SE本季度营收预计增65.79%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.argenx.com","stockEarnings":[{"period":"1week","weight":0.0131},{"period":"1month","weight":-0.0549},{"period":"3month","weight":0.1059},{"period":"6month","weight":0.066},{"period":"1year","weight":0.2866},{"period":"ytd","weight":0.0286}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Argenx Se根据荷兰法律于2008年4月25日成立，是一家私人有限责任公司（besloten vennootschap met beperkte aansprakelijkheid）。 于2014年5月28日，根据公证转换契约及修订，该公司转为上市有限责任公司（naamloze vennootschap）。 该公司是一家处于商业阶段的、全球性的、完全整合的生物制药公司，开发用于治疗严重自身免疫性疾病的差异化疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.007923},{"month":2,"riseRate":0.333333,"avgChangeRate":0.026997},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.02217},{"month":4,"riseRate":0.777778,"avgChangeRate":0.0372},{"month":5,"riseRate":0.555556,"avgChangeRate":0.061118},{"month":6,"riseRate":0.8,"avgChangeRate":0.059431},{"month":7,"riseRate":0.6,"avgChangeRate":0.070059},{"month":8,"riseRate":0.7,"avgChangeRate":0.017073},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.022149},{"month":10,"riseRate":0.666667,"avgChangeRate":0.037064},{"month":11,"riseRate":0.777778,"avgChangeRate":0.116374},{"month":12,"riseRate":0.444444,"avgChangeRate":0.116024}],"exchange":"NASDAQ","name":"Argenx SE","nameEN":"Argenx SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Argenx SE(ARGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Argenx SE(ARGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Argenx SE,ARGX,Argenx SE股票,Argenx SE股票老虎,Argenx SE股票老虎国际,Argenx SE行情,Argenx SE股票行情,Argenx SE股价,Argenx SE股市,Argenx SE股票价格,Argenx SE股票交易,Argenx SE股票购买,Argenx SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Argenx SE(ARGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Argenx SE(ARGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}